Recombinant anti-tumor fusion protein (Beijing Diweihuayu Biotech)
重组抗肿瘤融合蛋白（北京迪威华宇生物技术）
Report date: 2022/01/17 12:14:22
Base Information
Drug NameRecombinant anti-tumor fusion protein (Beijing Diweihuayu Biotech)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Diwei Huayu Bio-Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesBeijing Diwei Huayu Bio-Technology Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A